The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products from Tokyo-based Eisai by Hilton Pharma. The acquisition includes the rights to manufacture and commercialise the drugs Methycobal and Myonal in Pakistan. The transaction involves the transfer of trademarks, know-how and records related to these products under an asset purchase agreement sig